Shernan Holtan: We hope the need for years and years of immunosuppression due to Graft-versus-host disease is gone forever
Shernan Holtan, Associate Professor at University of Minnesota Health Clinics, recently shared a post by Transplantation and Cellular Therapy Journal, on X/Twitter:
“I’m honestly so proud of this trial and our team! Alex Hoover showing us important peds vs adult data with PTCy. That chronic Graft-versus-host disease CI curve
We hope the need for years and years of immunosuppression due to Graft-versus-host disease is gone forever.”
Quoting Transplantation and Cellular Therapy Journal’s post:
“The incidence of severe acute/chronic graft-versus-host disease is <6% in matched donor myeloablative conditioned hematopoietic cell transplantation with post-transplantation cyclophosphamide/tacrolimus/mycophenolate mofetil.”
For details click here.
Source: Shernan Holtan/Twitter and Transplantation and Cellular Therapy Journal/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023